CAR-T Cell Therapy Treatment
An advanced form of adoptive cellular immunotherapy that harnesses and enhances the patient’s own immune system to recognize and eliminate malignant cells with high specificity.
90%
Response In Leukemia
FDA
Approved Therapy
1
Single Infusion
Overview
This synthetic receptor enables T cells to directly identify tumor-associated antigens on cancer cells, independent of major histocompatibility complex (MHC) presentation. Once modified, the CAR-T cells are expanded in a controlled laboratory environment and subsequently infused back into the patient.
Mechanism of Action
Antigen-Binding Domain
Typically derived from a monoclonal antibody, this extracellular domain allows the T-cell to lock onto specific cancer cell markers.
Transmembrane Domain
This structural component anchors the receptor to the T-cell surface, ensuring stability during the attack phase.
Intracellular Signaling
Domains such as CD3ζ and costimulatory molecules like CD28 or 4-1BB activate the T-cell to proliferate and destroy the target.
Advantages
Highly Targeted
Specifically engineered to target cancer cells while sparing most healthy tissues.
Durable Remissions
The ability to induce long-lasting remission even in advanced stages.
Immune Surveillance
Modified cells can persist in the body, providing ongoing protection against recurrence.
Reference Efficacy
Effective in treatment-resistant or relapsed cancers where other lines have failed.
Clinical Applications
Acute Lymphoblastic Leukemia (ALL)
High success rates in treating children and young adults.
Diffuse Large B-cell Lymphoma
A leading treatment for this aggressive type of non-Hodgkin lymphoma.
SEARCH IN
frequently asked question
(Car-T Cell)
-
What is CAR T-cell therapy?
CAR T-cell therapy is an advanced immunotherapy in which a patient’s own T cells are genetically modified to better recognize and attack cancer cells, then reinfused back into the body.
-
Which cancers can be treated with CAR T-cell therapy?
It is primarily used for certain blood cancers, including specific types of leukemia and lymphoma. It is FDA-approved and shows high response rates in eligible patients.
-
What is the success rate of CAR T-cell therapy?
Success varies by cancer type, but in some forms of leukemia, response rates can reach up to 90%.
(TIL Therapy)
-
What is TIL therapy?
TIL (Tumor-Infiltrating Lymphocyte) therapy is an immunotherapy approach in which a patient’s own immune cells are harvested, expanded in the laboratory, and reinfused to fight cancer.
-
Is TIL therapy suitable for all types of cancer?
No. TIL therapy is currently used more commonly in certain solid tumors, especially metastatic melanoma. Patient suitability is determined on an individual basis.
-
What are the main advantages of TIL therapy?
Its personalized nature and its ability to strengthen the immune system in a targeted way are considered its main advantages.
